Table 1 Clinicopathologic characteristics of the 56 PBL patients with available follow-up data in our study
Variable | Total N (%) |
|---|---|
Patients | 56 |
Age (years) | |
  > 60 | 23 (41.1) |
  ≤ 60 | 33 (58.9) |
  Median (years) | 55.0 (range 10–79) |
Sex | |
  Male | 36 (64.3) |
  Female | 20 (35.7) |
Site(s) of involvement | |
  Lymph involvement | 13 (23.2) |
  Gastro-intestinal tractus | 10 (17.9) |
  Oral cavity | 9 (16.1) |
  Bone | 7 (12.5) |
  Soft tissue | 4 (7.1) |
  Ear, nose, throat site | 3 (5.4) |
  Maxillary sinus | 2 (3.6) |
  Skin | 3 (5.4) |
  Lung | 1 (1.0) |
  Adrenal gland | 1 (1.0) |
  Peritoneum | 1 (1.0) |
  Liver | 1 (1.0) |
  Pleura | 1 (1.0) |
Ann Arbor stage | |
  I or II | 35 (62.5) |
  III or IV | 21 (37.5) |
Immunohistochemistry | |
  CD38 | 28/31 (90.3) |
  CD138 | 29/42 (69.0) |
  MUM1 | 42/44 (95.4) |
  EBER | 10/20 |
  Ki67(median) | 80% |
Treatment | |
  Surgery | 4 (7.1) |
Chemotherapy | |
  CHOP | 43 (76.8) |
  DA-EPOCH | 3 (5.4) |
  Bor-based chemotherapy | 4 (7.1) |
  Other | 4 (7.1) |
  Radiation therapy | 2 (3.6) |
Therapy response | |
  CR | 25 (44.6) |
  PR | 17 (30.4) |
  SD | 1 (1.8) |
  PD | 13 (23.2) |
Status at last follow-up | |
  Dead | 22 (39.3) |
  Alive | 34 (60.7) |